Zobrazeno 1 - 10
of 29
pro vyhledávání: '"Scott Moseley"'
Publikováno v:
Orphanet Journal of Rare Diseases, Vol 14, Iss 1, Pp 1-9 (2019)
Abstract Background Hypophosphatasia (HPP) is a rare, inherited, metabolic bone disease caused by deficient tissue-non-specific isoenzyme of alkaline phosphatase activity that manifests as a broad range of signs/symptoms, including bone mineralizatio
Externí odkaz:
https://doaj.org/article/e61013f2358e47d4b95ced77ae4b7155
Autor:
Dawn Phillips, Ioannis C Tomazos, Scott Moseley, Gil L'Italien, Hugo Gomes da Silva, Sergio Lerma Lara
Publikováno v:
JBMR Plus, Vol 3, Iss 6, Pp n/a-n/a (2019)
ABSTRACT This investigation evaluated the reliability and validity of the 6‐Minute Walk Test (6MWT) in patients with pediatric hypophosphatasia (HPP). Children (aged 6 to 12 years; n = 11), adolescents (13 to 17 years; n = 4), and adults (18 to 65
Externí odkaz:
https://doaj.org/article/c01abcbd223a479086ae856f06803a45
Autor:
Aftab Ala, Tao Liang, Haiting Zhang, Linwen Zhang, Scott Moseley, Ping Guo, Meng Chen, Tracey Hall, Ming Li, Eugene Swenson, Wei-Jian Pan, Brian Meltzer, Ryan Pelto, Mark Ma
Publikováno v:
Abstracts.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1cfb54509978a7f8ac65da337d8186eb
https://doi.org/10.1136/gutjnl-2022-basl.53
https://doi.org/10.1136/gutjnl-2022-basl.53
Autor:
Michael P. Whyte, Andrew Denker, Frank Rauch, Priya S. Kishnani, Scott Moseley, M. Tariq Bhatti, Cheryl Rockman-Greenberg, Eric Watsky
Publikováno v:
Bone. 121:149-162
Hypophosphatasia (HPP) features low tissue-nonspecific alkaline phosphatase (TNSALP) isoenzyme activity resulting in extracellular accumulation of its substrates including pyridoxal 5'-phosphate (PLP), the principal circulating form of vitamin B6, an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::18523f559c9164453d7442dc7dc7bd57
https://doi.org/10.1016/j.bone.2018.12.011
https://doi.org/10.1016/j.bone.2018.12.011
Autor:
Kenji P Fujita, John W. Taylor, William H. McAlister, Dawn Phillips, Jill H. Simmons, Michael P. Whyte, Nada J. Salman, Nick Bishop, Scott Moseley, Mairead McGinn
Publikováno v:
The Lancet Diabetes & Endocrinology. 7:93-105
Summary Background Our previous phase 2, open-label study of 11 infants and young children with life-threatening perinatal or infantile hypophosphatasia showed 1 year safety and efficacy of asfotase alfa, an enzyme replacement therapy. We aimed to re
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::73cc1767302abce61a8c0bc321c5d2cc
https://doi.org/10.1016/s2213-8587(18)30307-3
https://doi.org/10.1016/s2213-8587(18)30307-3
Autor:
Tao Liang, Haiting Zhang, Linwen Zhang, Scott Moseley, Ping Guo, Meng Chen, Tracey Hall, Ming Li, Eugene Swenson, Wei-Jian Pan, Brian Meltzer, Ryan Pelto, Mark Ma
Publikováno v:
Journal of Hepatology. 77:S526
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::eb7a82cef06ce201bad51705dc9751cb
https://doi.org/10.1016/s0168-8278(22)01374-5
https://doi.org/10.1016/s0168-8278(22)01374-5
Autor:
Kathryn Dahir, Lothar Seefried, Priya S. Kishnani, Michael P. Whyte, Andrew Denker, Scott Moseley, Eric Watsky
Publikováno v:
Bone. 142
Hypophosphatasia (HPP) is the rare, inherited, metabolic bone disease characterized by low activity of the tissue-nonspecific isoenzyme of alkaline phosphatase (TNSALP) leading to excess extracellular inorganic pyrophosphate (PPi) and pyridoxal 5'-ph
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e9aa76914acdbfddd09ddc6c3d698e48
https://pubmed.ncbi.nlm.nih.gov/32987199
https://pubmed.ncbi.nlm.nih.gov/32987199
Publikováno v:
Journal of Bone and Mineral Research. 33:868-874
Hypophosphatasia (HPP) is the heritable metabolic disease characterized by impaired skeletal mineralization due to low activity of the tissue-nonspecific isoenzyme of alkaline phosphatase. Although HPP during growth often manifests with distinctive r
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ad92e2f64b993589458869a11472b506
https://doi.org/10.1002/jbmr.3377
https://doi.org/10.1002/jbmr.3377
Publikováno v:
Orphanet Journal of Rare Diseases
Orphanet Journal of Rare Diseases, Vol 14, Iss 1, Pp 1-9 (2019)
Orphanet Journal of Rare Diseases, Vol 14, Iss 1, Pp 1-9 (2019)
Background Hypophosphatasia (HPP) is a rare, inherited, metabolic bone disease caused by deficient tissue-non-specific isoenzyme of alkaline phosphatase activity that manifests as a broad range of signs/symptoms, including bone mineralization defects
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::37623345b1efa8d71bc5954b6585697d
http://europepmc.org/articles/PMC6698035
http://europepmc.org/articles/PMC6698035
Autor:
Nick Bishop, Jerry Vockley, Hideki Nakayama, Gabriel Á. Martos-Moreno, Christine Hofmann, Wolfgang Högler, Scott Moseley, Johannes G. Liese, Paul Harmatz, Cheryl Rockman-Greenberg, Kenji P Fujita
Publikováno v:
The Journal of Clinical Endocrinology and Metabolism
Biblos-e Archivo. Repositorio Institucional de la UAM
instname
Biblos-e Archivo. Repositorio Institucional de la UAM
instname
Context Long-term data on enzyme replacement treatment of hypophosphatasia (HPP) are limited. Objective To evaluate efficacy and safety of asfotase alfa in patients aged ≤5 years with HPP followed for up to 6 years. Design Phase 2 open-label study
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5924d6ac984b7d17c57f1010820207d5
https://eprints.whiterose.ac.uk/144580/7/jc.2018-02335.pdf
https://eprints.whiterose.ac.uk/144580/7/jc.2018-02335.pdf
